Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...

LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs ...

Eli Lilly is the most likely healthcare stock to reach a $1 trillion valuation, and I believe it could hit that plateau by 2027. Eli Lilly's stock has surged close to 400% in five years.

Eli Lilly down 19% in May, worst month since 2009. Underperformed S&P 500 by 24%, worst since August 2000. June shows promise, historically Lilly’s strongest month. Up Next: Get 5 Dark Horse ...

Eli Lilly is beefing up muscle health R&D, ... Ph.D., chief scientific officer at Lilly, discussed what Lilly wants to see from muscle-boosting drugs on an earnings call in February.

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. ... and earnings per share (EPS) of $20.17–$21.67 (on a GAAP basis), for a price to earnings ratio of ~37x. ...

Lilly is expected to post earnings of $5.56 per share for the current quarter, representing a year-over-year change of +41.8%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.5%.